US probing J&J's marketing activities of pain drug Nucynta
This article was originally published in Scrip
Executive Summary
Janssen Pharmaceuticals received a subpoena from the Office of Inspector General (OIG) at the Department of Health and Human Services seeking documents and information about the sales, marketing and promotional practices, including any remuneration of healthcare providers, related to the immediate- and extended-release formulations of the firm's chronic pain drug Nucynta (tapentadol), the firm's parent company, Johnson & Johnson, disclosed in a Securities & Exchange Commission filing late last week.